http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105461687-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2014-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105461687-B |
| titleOfInvention | Dihydropyridazinone-containing quinoline compound and application thereof |
| abstract | The invention relates to dihydropyridazinone-containing quinoline derivatives shown as a general formula I, and pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein substituents Ar and R are 1 、R 2 、R 3 X, Y, n have the meaning given in the description. The invention also relates to a compound of the general formula I, which has a strong effect of inhibiting c-Met kinase, and also relates to application of the compound and pharmaceutically acceptable salts, solvates or prodrugs thereof in preparing medicines for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, in particular to application in preparing medicines for treating and/or preventing cancers. 。 |
| priorityDate | 2014-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 112.